What exosomes are
Exosomes are extracellular vesicles, tiny membrane-bound packages released by cells. They carry proteins, lipids and genetic material such as messenger RNA, and they function as a communication system, delivering signals from one cell to another. In the body they play a real and important role in tissue signalling.
The aesthetic proposition builds on that biology. If exosomes derived from stem cells or other sources carry pro-regenerative signals, the argument runs, applying them to skin or scalp might stimulate repair, collagen production or hair growth. The mechanism is biologically interesting and the laboratory science is real.
The leap that requires scrutiny is from that laboratory biology to a bottled cosmetic product delivering a reliable clinical result in humans. Exosomes are fragile, their contents vary by source and processing, and a commercial product is a long way from a controlled laboratory preparation.
Source is a particular concern. Exosome products may be derived from various cell types, and the isolation and purification methods differ widely between manufacturers, as does the way the product is stored and handled once it reaches the clinic. Because there is no standardised, licensed cosmetic product to compare against, two treatments both described as exosome therapy may contain very different material at very different concentrations. That variability alone should temper any confident claim about what a given treatment will achieve.
The regulatory status in the UK
This is the part most often glossed over in marketing. In the UK there is no licence for injectable exosome products for cosmetic indications. Products derived from human tissue and intended for injection sit within a strict regulatory framework, and cosmetic exosome injectables do not have marketing authorisation for that use.
The absence of an injectable licence is not a technicality. It is the central fact a patient should weigh before agreeing to any exosome treatment.
In practice this means exosome products are generally used topically, most often applied to skin after a procedure such as microneedling or laser that has created channels in the surface. Applying an unlicensed biological product into freshly created skin channels raises its own safety questions, and it is not the same thing as a regulated injectable. The MHRA is the relevant authority, and any patient should confirm exactly what is being applied and how it is regulated. A clinic offering injectable exosomes for a cosmetic purpose is operating outside the licensed framework.
What the evidence does and does not show
The fair summary is that the human clinical evidence is thin. Much of the supporting science is laboratory or animal work, which is genuinely promising but does not establish a clinical result in people. The human studies that exist are small, often uncontrolled, and frequently connected to product suppliers.
What can reasonably be said:
- The underlying cell-signalling biology is real and actively researched
- Early laboratory and animal data on wound healing and hair follicle signalling is encouraging
- Some small human reports describe improvements in skin quality and hair density
What cannot yet be said with confidence:
- That commercial exosome products deliver a reliable, reproducible clinical result
- That the exosome content and quality is standardised between products
- That topical application after a procedure delivers intact, functional exosomes to where they are claimed to act
- That the effect exceeds that of the underlying microneedling or laser alone
That last point is important. Much of the visible improvement patients attribute to exosomes may be the result of the microneedling or laser performed at the same time. Without controlled comparison it is difficult to separate the two. The same evidential discipline applies across the regenerative field, as our assessment of what the polynucleotide evidence says discusses.
It is worth being clear about what a fair evidence bar looks like, because the phrase clinically proven is used loosely in this corner of the market. A meaningful claim would rest on controlled trials, ideally with a comparison arm that isolates the exosome product from the procedure it accompanies, blinded assessment, and independent funding. Very little of the exosome literature meets that bar. That does not prove the products do nothing; it means the confident marketing language is not yet backed by the kind of evidence a cautious patient should expect before paying a premium.
How they are used in practice
In UK clinics exosome products are typically offered as a topical add-on to a resurfacing or needling treatment, marketed as accelerating healing and enhancing results. Pricing in 2026 runs from roughly £400 to £900 per session, often on top of the base treatment cost, which our guide to what aesthetic treatments cost in the UK in 2026 places in context.
There is a plausible biological wrinkle in the topical route worth naming. Applying a product to skin that has just been needled or lasered does put it in contact with freshly created channels, which is the rationale for the timing. Whether intact, functional exosomes actually pass through those channels and reach the cells they are meant to signal, in sufficient quantity to act, is not established. It is entirely possible that the product is largely sitting on the surface while the visible benefit comes from the procedure beneath it. Until studies separate the two, that possibility should weigh on how a patient values the add-on.
The commercial logic is straightforward: a premium add-on with a compelling scientific story attached. That does not make it ineffective, but it does mean the incentive to overstate is strong, and the patient is often paying a premium for a benefit that has not been separated from the base procedure.
The hype cycle
Exosomes are a textbook example of the aesthetic hype cycle. A genuine and exciting area of biological research is picked up by marketing, compressed into a bottled product, and sold with confidence that the evidence does not yet support. The pattern is familiar from previous cycles around stem cells and growth factors.
None of this means exosomes will not eventually prove valuable. The biology is real and the research is ongoing. It means the current commercial offering is running well ahead of the clinical evidence, and a cautious patient is right to treat bold regenerative claims with scepticism until controlled human data catches up.
There is also a regulatory dimension to the hype that patients should weigh. When a product is marketed hard while sitting outside a licensed framework for the use being promoted, the marketing itself is a warning sign rather than a reassurance. Licensed medicines carry claims that a regulator has assessed. An unlicensed cosmetic product carries claims that no regulator has signed off, which places the entire burden of judgement on the patient and the clinic. That is precisely the situation where confident language should raise scrutiny, not lower it.
Questions worth asking
A patient considering an exosome treatment can cut through much of the marketing with a few direct questions. What exactly is the product, and what is its source? Is it applied topically or injected, and if injected, under what regulatory authorisation? What is the evidence that it adds anything beyond the microneedling or laser it accompanies?
A clinic that answers these plainly, and is candid about the limits of the evidence, is demonstrating the right posture. One that responds only with regenerative marketing language is telling you something too. Verifying the practitioner and the setting, as our explainer on what an aesthetic clinic actually means in UK law describes, is a sensible additional step.
